Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core — Joel Marvin Guthridge (OKLAHOMA MEDIC
Project Summary The successful Accelerating Medicines Partnership in RA/Lupus (AMP1) program focused on deconstructing disease tissues through single-cell transcriptomic technologies. AMP in Autoimmun
| Project title | Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core |
|---|---|
| Project number | 5UC2AR081032-03 |
| PI name | Joel Marvin Guthridge |
| Institution | OKLAHOMA MEDICAL RESEARCH FOUNDATION |
| Funding mechanism | UC2 |
| Agency | NIAMS |
| Award amount | $3.70M |
| Fiscal year | 2024 |
| Project start | 2022-03-23T00:00:00 |
| Project end | 2026-12-31T00:00:00 |
| Abstract | Project Summary The successful Accelerating Medicines Partnership in RA/Lupus (AMP1) program focused on deconstructing disease tissues through single-cell transcriptomic technologies. AMP in Autoimmun |
| Key terms | <2'-Deoxy-2-chloroadenosine><2-CDA><2-Chloro-2'-deoxyadenosine><2-Chlorodeoxyadenosine><2-chloro-2'- |
$799/mo
Try GrantRadar →